Search research articles
Contact Us
Filters
Showing results (131-140 of 181) with videos related to
Page
of 19
Sort By:
Investigational New Drugs
|
September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
The New England Journal of Medicine
|
June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Eileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Lancet (London, England)
|
September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Nature Medicine
|
January 9, 2024
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Shubham Pant, Zev A Wainberg, Colin D Weekes, et al.
Gynecologic Oncology
|
November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
Shannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Cancer Medicine
|
July 12, 2021
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
Chirayu Mohindroo, Merve Hasanov, Jane E Rogers, et al.
Future Oncology (London, England)
|
February 12, 2025
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
The Oncologist
|
July 17, 2024
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma
Mahmoud Yousef, Mark W Hurd, Abdelrahman Yousef, et al.
Annals of Surgery
|
January 17, 2023
Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma
Timothy E Newhook, Timothy J Vreeland, James F Griffin, et al.
Page
of 19
Search research articles
Search
Showing results (131-140 of 181) with videos related to
Sort By:
Page
of 19
Investigational New Drugs
|
September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
The New England Journal of Medicine
|
June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Eileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Lancet (London, England)
|
September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Nature Medicine
|
January 9, 2024
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Shubham Pant, Zev A Wainberg, Colin D Weekes, et al.
Gynecologic Oncology
|
November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
Shannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Cancer Medicine
|
July 12, 2021
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
Chirayu Mohindroo, Merve Hasanov, Jane E Rogers, et al.
Future Oncology (London, England)
|
February 12, 2025
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
The Oncologist
|
July 17, 2024
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma
Mahmoud Yousef, Mark W Hurd, Abdelrahman Yousef, et al.
Annals of Surgery
|
January 17, 2023
Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma
Timothy E Newhook, Timothy J Vreeland, James F Griffin, et al.
Page
of 19